Literature DB >> 2697397

Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group.

H H Gerhartz1, G Visani, A Delmer, H Zwierzina, M Ribeiro, A Jacobs, R Marcus, M Baumelou, D Fière, B Labar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2697397

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  4 in total

1.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

2.  Regulation of granulocytosis in inflammatory disease and in leukemia.

Authors:  P Reizenstein; L Stenke
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

3.  Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? A report on 77 cases.

Authors:  L Detourmignies; E Wattel; J L Laï; F Bauters; P Fenaux
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

4.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.